Literature DB >> 24899687

Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis.

Bin Guan1, Yohan Suryo Rahmanto1, Ren-Chin Wu1, Yihong Wang1, Zhong Wang1, Tian-Li Wang1, Ie-Ming Shih2.   

Abstract

The chromatin remodeling gene, ARID1A, has been implied as a tumor suppressor, and its somatic inactivating mutations occur in a wide variety of human cancers, most frequently in ovarian and uterine endometrioid and ovarian clear cell carcinomas. Tumors with ARID1A mutations also frequently harbor PTEN or PIK3CA mutations, suggesting their collaboration in tumorigenesis. Here, we used a conditional knockout mouse model in which Arid1a and Pten were deleted either individually or in combination in the mouse ovarian surface epithelium. After 6 months, 59.1% of mice with Arid1a and Pten double knockout developed ovarian endometrioid or undifferentiated carcinoma, whereas the remaining mice showed hyperplasia of ovarian surface epithelium. In contrast, 52 mice with homozygous or heterozygous deletion in either Arid1a or Pten did not develop ovarian lesions. These results demonstrate that inactivation of Arid1a alone is insufficient for tumor initiation but it requires additional genetic alteration(s) such as Pten deletion to drive tumorigenesis.
© The Author 2014. Published by Oxford University Press. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24899687      PMCID: PMC4056776          DOI: 10.1093/jnci/dju146

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  26 in total

1.  Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.

Authors:  Daniela M Dinulescu; Tan A Ince; Bradley J Quade; Sarah A Shafer; Denise Crowley; Tyler Jacks
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

2.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

3.  An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Authors:  Kathryn M Kinross; Karen G Montgomery; Margarete Kleinschmidt; Paul Waring; Ivan Ivetac; Anjali Tikoo; Mirette Saad; Lauren Hare; Vincent Roh; Theo Mantamadiotis; Karen E Sheppard; Georgina L Ryland; Ian G Campbell; Kylie L Gorringe; James G Christensen; Carleen Cullinane; Rodney J Hicks; Richard B Pearson; Ricky W Johnstone; Grant A McArthur; Wayne A Phillips
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

4.  Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo.

Authors:  M Groszer; R Erickson; D D Scripture-Adams; R Lesche; A Trumpp; J A Zack; H I Kornblum; X Liu; H Wu
Journal:  Science       Date:  2001-11-01       Impact factor: 47.728

5.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

6.  Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.

Authors:  Melissa K McConechy; Jiarui Ding; Janine Senz; Winnie Yang; Nataliya Melnyk; Alicia A Tone; Leah M Prentice; Kimberly C Wiegand; Jessica N McAlpine; Sohrab P Shah; Cheng-Han Lee; Paul J Goodfellow; C Blake Gilks; David G Huntsman
Journal:  Mod Pathol       Date:  2013-06-14       Impact factor: 7.842

7.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

8.  Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.

Authors:  Rong Wu; Neali Hendrix-Lucas; Rork Kuick; Yali Zhai; Donald R Schwartz; Aytekin Akyol; Samir Hanash; David E Misek; Hidetaka Katabuchi; Bart O Williams; Eric R Fearon; Kathleen R Cho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743

9.  Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Authors:  Siân Jones; Meng Li; D Williams Parsons; Xiaosong Zhang; Jelle Wesseling; Petra Kristel; Marjanka K Schmidt; Sanford Markowitz; Hai Yan; Darell Bigner; Ralph H Hruban; James R Eshleman; Christine A Iacobuzio-Donahue; Michael Goggins; Anirban Maitra; Sami N Malek; Steve Powell; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Hum Mutat       Date:  2011-11-23       Impact factor: 4.878

10.  Dedifferentiated endometrioid adenocarcinoma: An under-recognized but aggressive tumor?

Authors:  Emily S Wu; Ie-Ming Shih; Teresa P Díaz-Montes
Journal:  Gynecol Oncol Case Rep       Date:  2013-03-06
View more
  51 in total

1.  Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.

Authors:  Yali Zhai; Rork Kuick; Courtney Tipton; Rong Wu; Michael Sessine; Zhong Wang; Suzanne J Baker; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2015-09-15       Impact factor: 7.996

Review 2.  Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.

Authors:  Kazuaki Takahashi; Masataka Takenaka; Ayako Kawabata; Nozomu Yanaihara; Aikou Okamoto
Journal:  Int J Clin Oncol       Date:  2020-01-27       Impact factor: 3.402

Review 3.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

4.  Arid1a controls tissue regeneration.

Authors:  Shuai Wu; Rugang Zhang; Benjamin G Bitler
Journal:  Stem Cell Investig       Date:  2016-08-09

Review 5.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

6.  Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.

Authors:  Rong Wu; Yali Zhai; Rork Kuick; Anthony N Karnezis; Paloma Garcia; Anum Naseem; Tom C Hu; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2016-11       Impact factor: 7.996

7.  CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.

Authors:  Ayse Ayhan; Elisabetta Kuhn; Ren-Chin Wu; Hiroshi Ogawa; Asli Bahadirli-Talbott; Tsui-Lien Mao; Haruhiko Sugimura; Ie-Ming Shih; Tian-Li Wang
Journal:  Mod Pathol       Date:  2016-10-21       Impact factor: 7.842

Review 8.  SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.

Authors:  Takeshi Fukumoto; Elizabeth Magno; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2018-07-23       Impact factor: 5.852

Review 9.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

10.  Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.

Authors:  Yohan Suryo Rahmanto; Jin-Gyoung Jung; Ren-Chin Wu; Yusuke Kobayashi; Christopher M Heaphy; Alan K Meeker; Tian-Li Wang; Ie-Ming Shih
Journal:  J Biol Chem       Date:  2016-03-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.